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Background: In HIV-infected populations in developed countries, the most recent published cancer incidence
trend analyses are only updated through 2008. We assessed changes in the distribution of cancer types and
incidence trends among HIV-infected patients in North Carolina up until 2011.
Methods: We linked the University of North Carolina Center for AIDS Research HIV Clinical Cohort, an observational
clinical cohort of 3141 HIV-infected patients, with the North Carolina Cancer registry. Cancer incidence rates were
estimated across calendar years from 2000 to 2011. The distribution of cancer types was described. Incidence trends
were assessed with linear regression.
Results: Across 15,022 person-years of follow-up, 202 cancers were identified (incidence rate per 100,000 person-
years [IR]: 1345; 95% confidence interval [CI]: 1166, 1544). The majority of cancers were virus-related (61%), including
Kaposi sarcoma (N = 32) (IR: 213; 95%CI: 146, 301), non-Hodgkin lymphoma (N = 34) (IR: 226; 95%CI: 157, 316), and
anal cancer (N = 16) (IR: 107; 95%CI: 61, 173). Non-Hodgkin lymphoma was observed to decrease from 2000 to 2011
(decline of 15 cases per 100,000 person-years per calendar year, 95%CI: -27, -3). No other changes in incidence or
changes in incidence trends were observed for other cancers (all P > 0.20).
Conclusions: We observed a substantial burden of a variety of cancers in this population in the last decade. Kaposi
sarcoma and non-Hodgkin lymphoma were consistently two of the greatest contributors to cancer burden across
calendar time. Cancer rates appeared stable across calendar years, except for non-Hodgkin lymphoma, which
appeared to decrease throughout the study period.
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Among HIV-infected patients increased risk of cancer, such
as Kaposi sarcoma (KS) and non-Hodgkin lymphoma
(NHL), has been recognized since the beginning of the HIV
epidemic [1,2]. This is believed to be a result of
HIV-induced immune suppression hindering the control
of cancer-associated viruses, as well as direct effects of
HIV replication [3]. While KS and NHL still contribute
substantially to morbidity, the spectrum of cancers seen in
people living with HIV is changing rapidly [4]. Cancer
registries have been extensively used to study these trends* Correspondence: dirk_dittmer@med.unc.edu
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reproduction in any medium, provided the or[5,6]. However, the most recent data from registries and
prospective cohort studies has lagged behind by many
years. The most recent US-based and Swiss-based cohort
trend analyses end in 2006 and 2007 [7-9], while
Globocan, the International Agency for Research in
Cancer-based worldwide cancer registry, reports data up
to 2008 [6].
We investigated cancer incidence trends in the University
of North Carolina (UNC) CFAR HIV Clinical Cohort
(UCHCC) up to 2011, hypothesizing that declining
cancer incidence trends that marked the introduction
of combination antiretroviral therapy (ART) may plateau
in more recent years at a level still significantly elevated
compared to the general population.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study population
For this study we linked UCHCC study participants with
North Carolina state cancer registry data between 2000
and 2011. The UCHCC is an observational clinical
cohort which includes all HIV-infected patients who
have received HIV primary care at UNC since 1996
[10]. The UCHCC includes demographic, laboratory,
and diagnosis data, including thorough reviews and
adjudications of all cancer diagnoses based on patient
medical records. The North Carolina state cancer
registry is also administered through UNC. This study
was approved by the UNC Institutional Review Board.
This research was not experimental, but observational
in nature and was in compliance with the Helsinki
Declaration.
Statistical analysis
Patients contributed time during all years in which they
were in care at UCHCC, as indicated by clinic visits and the
presence of at least one HIV RNA level or CD4 cell count
result. Overall clinical and demographic characteristics
were described weighted by person-time. Time-varying
characteristics, such as age and laboratory values, were
updated for each year. Laboratory values were based on
the first measurement in a given year. For cancer cases,
the laboratory values measured closest to the date of
cancer diagnosis were used. Cancer incidence rates
for each calendar year were calculated as the number
of diagnoses divided by the number of person-years.
If a patient was diagnosed with multiple cancers, all
cancer diagnoses were counted.
To estimate absolute changes in cancer incidence across
calendar time we used linear regression. Additionally,
to test whether incidence trends were changing across
calendar years for the most frequent cancer types we
relied on broken stick regression [11]. Similar techniques
have been used previously to uncover cancer trends in
AIDS populations [12,13]. Broken stick regression fits
two linear piecewise regression lines and determines
the breakpoint at which the regression slope changes.
Likelihood ratio tests (LRT) were used to evaluate
improvements in model fit with one added breakpoint.
All analyses were done in SAS version 9.2 and R
version 2.15.1.
Results
From Jan. 1, 2000 through Aug. 1, 2011, 3141 HIV-infected
patients attended at least one clinic visit, and contributed a
total of 15,022 person-years of observation. We observed a
total of 202 cancer cases in this study population, including
a wide variety of cancer types (Figure 1). In absolute
numbers of cases, KS (N = 32) and NHL (N = 34) were
the most common cancers in this HIV-infected population.Among the human papillomavirus (HPV)-associated
cancers, anal cancer was common (N = 16), while invasive
cervical cancer was rare (N = 2). Lung cancer was the most
frequent non-AIDS-defining cancer (NADC) (N = 22). As a
group, NADCs were more frequent than AIDS-defining
cancers (ADCs) (134 NADC cases vs. 68 ADC cases);
however, individually each NADC cancer type was less
common than either KS or NHL.
Overall 30% of patients were female, 59% were black,
and 31% were white (Table 1). Over time, the median
patient age was 43 (IQR: 36–50), the median CD4 count
was 440 cells/mm3 (IQR: 244–660), and the median viral
load was 2.4 log10 copies/ml (IQR: <1.7-4.1). Patient
demographic and clinical characteristics changed across
calendar years of this study. In more recent calendar
years patients receiving HIV care were older, with higher
CD4 cell counts and were more likely to have HIV RNA
levels below the limit of detection (Table 1).
Among all cancer cases, the median CD4 count at
cancer diagnosis was 244 cells/mm3 (IQR: 109–458),
lower than the median CD4 count observed in the overall
patient population. CD4 counts at diagnosis were lower
for KS cases (median: 69 cells/mm3; IQR: 34–227) and
NHL cases (median: 153 cells/mm3; IQR: 89–263), but
were more similar to the entire patient population for
other cancer cases (median: 370 cells/mm3; IQR:
159–582). Six of the 32 KS cases were the presenting
diagnoses for HIV. Cancer cases had a median HIV RNA
at cancer diagnosis of 2.3 log10 copies/ml (IQR: <1.7, 4.3)
similar to the median of 2.4 log10 copies/ml observed in
the overall patient population. However, it was higher in
KS cases (median: 4.4 log10 copies/ml; IQR: 2.2, 5.2) and
NHL cases (median: 3.4 log10 copies/ml; IQR: 2.6, 5.0),
but lower in other cancer cases (median: <1.7 log10
copies/ml; IQR: <1.7, 2.9). When compared to the
rest of the patient population, cancer cases were also
more likely to be male (83% vs. 70%), men who have sex
with men (40% vs. 35%), and older (median age 47 years vs.
43 years). Antiretroviral naïve patients contributed 16% of
all follow-up time, while 21% of cancers were diagnosed in
patients who were antiretroviral naive.
The overall incidence rate of NHL was 226 cases per
100,000 person-years (95%CI: 157, 316) but declined
relatively consistently from 2000 through 2011 with a
decline of 15 cases per 100,000 person-years per calendar
year (95%CI: -27, -3) (Figure 2). While KS was the
next most common cancer (IR: 213; 95%CI: 146, 301),
a statistically significant increasing or decreasing trend
was not found (2 cases per 100,000 person-years decrease
per year, 95%CI: -22, 19). For lung cancer we observed an
incidence rate of 146 cases per 100,000 person-years
(95%CI: 92, 222). While lung cancer incidence appeared
to increase over time, a significant trend was not identified
(8 cases per 100,000 person-years increase per years, 95%
Figure 1 Cumulative cancer counts in the University of North Carolina Center for AIDS Research HIV clinical cohort (2000 – 2011).
*Other includes vulvar cancer, multiple myeloma, throat cancer, unspecified lymphoma, and other unspecified malignancies. NHL = Non-Hodgkin
Lymphoma, KS = Kaposi sarcoma, GI = Gastrointestinal.
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cases per 100,000 person-years (95%CI: 61, 173) showed
no clear changes in incidence over time. We did not ob-
serve incidence rate trends across calendar years for
any of the other cancers considered (all P for trend >
0.20). Additionally, broken stick regression models did
not demonstrate a statistically significant improve-
ment in model fit, indicating the absence of detect-
able changes in cancer incidence trends over time.
For most cancers, the number of cases was too small
to discern incidence trends with no recorded cases in
many calendar years.
Discussion
We observed a substantial decline in NHL throughout
the study period from 2000 to 2011. This demonstrates
a continued decline from prior studies that showed
decreasing NHL incidence up until 2006 [7,8,14]. Declines
in prior studies were attributed to the introduction anddissemination of ART; while the continued decline in NHL
we observe may be due to earlier initiation of effective ART
as evidenced by the higher CD4 counts observed over time.
Interestingly, a decreasing trend over calendar time was not
evident for KS. Additionally, no clear trends over calendar
time were identified for NADCs.
In our study, less than 20% of KS cases were the
presenting diagnosis for HIV, while close to 30% of
KS cases developed in patients with CD4 counts
greater than 200 cells/mm3, and more than 20% developed
in patients with undetectable HIV RNA. An interesting
development in recent years has been the emergence of
KS in subjects on successful long-term ART [15]. These
subjects may be the reason why KS incidence in recent
years remains significant and unlike NHL did not decline
further. Our observation suggests that the damage done
by initial HIV infection, ongoing immune activation [16],
sub-optimal immune reconstitution [17] and perhaps
long-term antiretroviral exposure continues to place
Figure 2 Graph of selected cancer trends in the University of North Carolina Center for AIDS Research HIV clinical cohort (2000–2011).
Circles represent observed incidence rate in each calendar year. Dotted line represents trend over time estimated from linear regression. NHL =
Non-Hodgkin lymphoma, KS = Kaposi sarcoma.
Table 1 Demographic and clinical characteristics of patients in the University of North Carolina Center for AIDS
Research HIV Clinical Cohort, stratified by calendar year intervals 2000-2011
Characteristic N (%) 2000-2002 2003-2005 2006-2008 2009-2011 Total P*
Total 1866 1849 1843 1767 3141
Female sex 598 (31.8) 601 (32.3) 544 (29.3) 514 (28.4) 932 (29.7) 0.03
Race
Black 1136 (61.0) 1088 (58.9) 1047 (57.0) 997 (56.4) 1862 (59.3)
White 591 (31.7) 610 (33.0) 596 (32.3) 563 (31.9) 962 (30.6)
Other 142 (7.5) 153 (8.2) 202 (10.9) 207 (11.7) 317 (10.1) <0.01
MSM 566 (30.3) 623 (33.6) 640 (34.6) 516 (29.2) 889 (28.3) <0.01
IDU 261 (14.0) 248 (13.4) 208 (11.2) 152 (8.6) 340 (10.8) <0.01
Age (years)† 40 (34–46) 42 (36–49) 44 (37–51) 46 (38–52) 43 (36–50) <0.01
CD4 cell count (cells/mm3) † 376 (181–602) 403 (218–621) 440 (251–657) 519 (335–737) 440 (244–660) <0.01
HIV RNA (log10 copies/ml)
† 2.92 (2.30-4.47) 2.73 (BLD-4.45) 2.05 (BLD-4.05) BLD (BLD-2.58) 2.37 (BLD-4.11) <0.01
ART experience (person-years after ART exposure)‡ 3322 (81.6) 3505 (83.7) 3680 (83.8) 3871 (88.0) 14378 (84.3) <0.01
*P-values from Chi-squared test for categorical and binary characteristics, and Kruskal-Willis test for continuous characteristics. Undetectable HIV RNA results were
assigned a value of half the limit of detection for the purposes of assessing trends across time.
†Median (Interquartile Range) presented for continuous characteristics.
‡The number of years of follow-up within the time interval contributed by ART-experienced patients and the percentage of all follow-up within the time interval
that was contributed be ART-experienced patients.
BLD: below limit of detection (<50 copies/mL); ART: antiretroviral therapy; MSM: men who have sex with men; IDU: injection drug user.
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Longer survival for HIV-infected patients may also allow
more time for the emergence of KS. Viral cancers have a
long lag time between primary infection and clinical
disease. KS in HIV + patients manifests itself approxi-
mately seven years after seroconversion for KS-associated
herpesvirus [18,19]. As such, the initiating event for
cancer that manifests itself clinically in the early periods
of widely available ART could have taken place when
patients were exposed to less than optimal antiretroviral
therapy or no therapy at all.
While a number of NADCs were observed in our
cohort, incidence trends were not apparent for anal
cancer or lung cancer, the most frequent types. A recent
North American multi-site study of anal cancer including
the UCHCC population also found no change in incidence
between 2000–2003 and 2004–2007 [20]. Shiels et al.
suggest that the clinical impression of more and more
NADCs in recent years is largely due to the aging effect of
the HIV + population [4]. The HIV population may face
larger increases in cancer risk than the general population
with advancing age due to more cumulative exposure
to environmental carcinogens such as tobacco and
alcohol. We urgently need to understand how anti-cancer
regimens and ART drugs interact, in order to develop
optimal treatment approaches. While the AIDS Malignancy
Consortium is beginning to identify such approaches for
NHL and KS, further studies will be needed to address
similar concerns in treating NADCs in HIV-infected
patients [21,22]. In contrast to the high incidence of
anal cancer, few cases of cervical cancer were observed.
This is in part because our patient population was
disproportionately male, but also likely serves as an
indicator of the success of efforts to screen and treat
premalignant cervical lesions.
Our study is noteworthy because we included over
10 years of data spanning the most recent calendar years
(2000–2011). During these years new antiretroviral
agents and their combination were introduced with
better tolerability and greater efficacy in controlling HIV
replication [23,24]. The improved effectiveness of these
agents is demonstrated in part by the higher CD4 cell
counts and greater proportion of our study population
with suppressed HIV RNA levels in more recent calendar
years. Most prior studies assessing cancer incidence trends
did not cover the most recent years [5,7] . Although our
study focuses on a study population receiving care at one
academic center, it represents an area of the US with
an increasingly large burden of HIV, including a large
proportion of women (almost one-third), and large
percentage of African American patients. Also close
to a third of this cohort resides in rural areas [25].
Our observations reflect these aspects of the changing
HIV population [26,27].These data do not take into account recent evidence
supporting the benefits of earlier ART initiation and the
subsequent changes in HIV treatment recommendations in
the U.S [23,28,29]. It is likely that as these new recommen-
dations are phased in, the spectrum of malignancies
affecting HIV-infected individuals will change. Data
on intensity or duration of tobacco use were not
available, but this was likely a major contributor to the
high incidence of lung cancer.
In the calendar years of our study, no decreases in
incidence were apparent for KS or NADCs. Given this
consistent cancer burden, the lack of validation of most
cancer treatment regimens in the HIV population, and the
high cancer risk compared to the general population,
a focus on increased screening and prevention efforts
is warranted.
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